Will Rescheduling Hydrocodone Combination Products Actually Reduce Abuse?

Published Online: Thursday, January 16, 2014
Follow Pharmacy_Times:
In this video, Jeff Fudin, PharmD, FCCP, adjunct associate professor at the Albany College of Pharmacy and adjunct assistant professor at the UCONN School of Pharmacy, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.

This is the part of a series of videos in which Dr. Fudin argues against categorizing hydrocodone combination products as Schedule II drugs, and Mary Lynn McPherson, PharmD, argues in favor of doing so. (Drs. McPherson and Fudin were assigned to take these positions for a session at the American Society of Health-System Pharmacists 2013 Midyear Clinical Meeting in Orlando, and their arguments do not necessarily reflect their personal positions on the issue.)

These videos were filmed at the ASHP 2013 Midyear Clinical Meeting in Orlando.

Related Articles
Updated REMS attempts to stem the flow of extended-release, long-acting opioids to addicts while ensuring patients in severe pain retain access.
A University of Kentucky pharmacy professor has developed a nasal spray of naloxone (Narcan) to treat potentially fatal overdoses from heroin and prescription opioids.
Drugs that contain hydrocodone will be moved to a more restrictive category of the Controlled Substances Act.
Latest Issues
$auto_registration$